Previous 10 | Next 10 |
Galapagos ( GLPG ) FY2019 results ((€)): More news on: Galapagos NV, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Galapagos (NASDAQ: GLPG ): Q4 net income of €149.8M Revenue of €844.99M (+192.5% Y/Y) Press Release More news on: Galapagos NV, Earnings news and commentary, Healthcare stocks news,
Hutchison China MediTech (NASDAQ: HCM ) initiated with Buy rating and $38 (38% upside) price target at Goldman Sachs. More news on: Hutchison China MediTech Limited, Eidos Therapeutics, Inc., Intra-Cellular Therapies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Biotech investing is generally cyclic in nature. The interplay between innovation and patent expirations makes many of these companies prone to enormous swings in revenue every couple of years. To smooth out the edges, biotechs must continually restock the cupboard through a mix of organic pipel...
Source: Barron's Gilead ( GILD ) reported a Q4 revenue of $5.88 billion, Non-GAAP EPS of $1.30 and GAAP EPS of $2.12. The stock is flat post-earnings. I have been bearish on Gilead for a few years now. The company's top line has gone through fits and starts and it will likely continue th...
With a market cap of about $83 billion, Gilead Sciences (NASDAQ: GILD) is one of the largest biotech companies in the world. However, big doesn't mean buy, and there are several reasons why investors should think twice before investing in Gilead Sciences. First, the company's stock is curren...
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...
2020 started off well for the markets despite the Coronavirus outbreak. The earnings season kicked off in which consumer companies are outperforming yet again with Apple ( AAPL ) and Amazon ( AMZN ) at the forefront. I believe we are in an environment where excessive risk-taking is applauded...
Ziopharm Oncology ( ZIOP ) announced its plan to issue equity shares. The company reported that it plans to issue nearly 27.8 million shares, not including underwriters’ overallotment which will likely result in the issue of additional 4.2 million shares. The issue will be priced at $...
Thesis: Gilead Sciences ( GILD ) has been relatively stagnant since the end of FY15 with the fall of its Hepatitis C ((HCV)) portfolio sales. Gilead's HCV sales for FY15 reached levels near $19 billion; current trailing 12-month HCV sales now sit a bit over $3 billion. However, Gilead has ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...